Aptose Biosciences begins TUSCANY trial with innovative AML triplet therapy

Aptose Biosciences Inc., a clinical-stage precision oncology company, has reached a significant milestone in its quest to transform acute myeloid leukemia (AML) treatment. The company ... Read More